Crucell Holland B.v.

Janssen Vaccines & Prevention B.v.

Epimmune Inc.

Elissa Keogh

Gabriel Pascual

Jehangir Wadia

Robert Anthony Williamson

Alessandro D Sette

Esteban Celis

John Sidney

Robert W Chesnut

Scott Southwood

John D Fikes

Provided herein are antibodies or antigen-binding fragments thereof that immunospecifically bind to the fusion (F) protein of Respiratory Syncytial Virus (RSV). Also provided are methods for of prevention, treatment and diagnosis of viral infection and/or the treatment of one more symptoms of RSV-mediated disease. Methods of generating antibodies that immunospecifically bind RSV F protein also are provided.

Anti-human Respiratory Syncytial Virus (RSV) antibodies and methods of use

Anti-human respiratory syncytial virus (RSV) antibodies and methods of use

Antibodies against human respiratory syncytial virus (RSV) and methods of use

A composition or vaccine composition comprising eight isolated epitopes consisting of YLSGANLNV (SEQ. ID. NO: 1), IMIGVLVGV (SEQ. ID. NO: 2), KLBPVQLWV (SEQ. ID. NO: 3), SMPPPGTRV (SEQ. ID. NO: 4), KVAELVHFL (SEQ. ID. NO: 5), YLQLVFGIEV (SEQ. ID. NO: 6), RLLQETELV (SEQ. ID. NO: 7), and, VVLGVVFGI (SEQ. ID. NO: 8).

HLA class I A2 tumor associated antigen peptides and vaccine compositions

Growing community of inventors

San Diego, CA, United States of America

Elissa Keogh